Trial Profile
Cardiovascular safety of mirabegron versus oxybutynin in patients with overactive bladder.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2017
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Oxybutynin
- Indications Overactive bladder
- Focus Adverse reactions
- 20 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management